Nectar Biopharma Private Ltd has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nectar Biopharma Private Limited, along with promoter Saurabh Goyal and promoter group members (Smita Goyal, Aryan Goyal, Payal Goyal), has filed a declaration with NSE, BSE, and the Audit Committee of Nureca Limited. Under Regulation 31(4) of the SEBI Takeover Regulations, they have confirmed that no encumbrance (such as pledge, lien, or charge) has been created on the equity shares of Nureca Limited during the financial year ended March 31, 2025. This is a routine annual compliance filing required from promoters of listed companies. The declaration covers all shares held by the promoter, promoter group members, and persons acting in concert with them.
This is a routine regulatory compliance filing and has no direct impact on the stock price. It reassures shareholders that promoters have not pledged or otherwise encumbered their shares, indicating stable promoter shareholding without leveraging risks.